MannKind (MNKD) to Post Quarterly Earnings on Wednesday

MannKind (NASDAQ:MNKD) is projected to issue its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.02) per share and revenue of $108.8040 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.03). MannKind had a negative return on equity of 11.21% and a negative net margin of 6.63%.The business had revenue of $90.17 million during the quarter, compared to the consensus estimate of $105.38 million. During the same quarter last year, the firm posted $0.04 earnings per share. MannKind’s revenue was up 15.1% compared to the same quarter last year. On average, analysts expect MannKind to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Trading Down 2.8%

Shares of NASDAQ MNKD opened at $3.80 on Tuesday. MannKind has a twelve month low of $2.23 and a twelve month high of $6.51. The firm has a 50-day moving average of $3.90 and a two-hundred day moving average of $3.80. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -54.28 and a beta of 1.12.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on MNKD. Zacks Research downgraded shares of MannKind from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 7th. Mizuho reduced their target price on shares of MannKind from $8.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. HC Wainwright restated a “buy” rating on shares of MannKind in a research report on Thursday, July 23rd. Wall Street Zen raised MannKind from a “sell” rating to a “hold” rating in a report on Sunday, July 5th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of MannKind in a research report on Wednesday, July 8th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, MannKind has a consensus rating of “Moderate Buy” and a consensus price target of $9.34.

Insider Activity

In related news, Director Steven B. Binder sold 16,940 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $3.29, for a total value of $55,732.60. Following the completion of the sale, the director owned 808,008 shares in the company, valued at approximately $2,658,346.32. This represents a 2.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On MannKind

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in shares of MannKind by 36.2% in the fourth quarter. State Street Corp now owns 14,623,269 shares of the biopharmaceutical company’s stock valued at $82,914,000 after purchasing an additional 3,883,071 shares in the last quarter. Rubric Capital Management LP acquired a new stake in shares of MannKind in the third quarter worth $61,297,000. UBS Group AG grew its holdings in shares of MannKind by 146.7% during the third quarter. UBS Group AG now owns 5,194,739 shares of the biopharmaceutical company’s stock valued at $27,896,000 after buying an additional 3,088,820 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of MannKind by 10.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,443,603 shares of the biopharmaceutical company’s stock valued at $25,195,000 after buying an additional 426,921 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its position in MannKind by 25.5% during the second quarter. Qube Research & Technologies Ltd now owns 4,065,904 shares of the biopharmaceutical company’s stock valued at $15,206,000 after buying an additional 825,608 shares during the period. 49.55% of the stock is currently owned by hedge funds and other institutional investors.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).